Biomarker: | BCR-ABL1 fusion |
---|---|
Cancer: | Acute Myelogenous Leukemia |
Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
Direction: | Sensitive |